September 7, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Jason Drory, Attorney
Re: | Navidea Biopharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-274246 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-274246) (the “Registration Statement”) to become effective at 4:30 p.m. Eastern Time on September 8, 2023, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Bill Mower of Maslon LLP, counsel to the registrant, at (612) 672-8358.
Very truly yours,
NAVIDEA BIOPHARMACEUTICALS, INC.
By: /s/ Craig Dais
Craig Dais.
Chief Financial Officer
cc: William M. Mower, Maslon LLP
